 Galera Therapeutics, Inc. Nasdaq: GRTX, a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of 12.00 per share, for total gross proceeds of 60.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Galera. All of the common stock is being offered by Galera. 